Advertisement
Alnylam Pharmaceuticals, Inc. (ALNY)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Follow
At close: 04:00PM EST
After hours:
| Previous Close | 246.80 |
| Open | 248.90 |
| Bid | 244.71 x 100 |
| Ask | 244.99 x 100 |
| Day's Range | 243.35 - 248.90 |
| 52 Week Range | 141.98 - 304.39 |
| Volume | |
| Avg. Volume | 862,098 |
| Market Cap | 31.586B |
| Beta (5Y Monthly) | 0.39 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.62 |
| Earnings Date | Feb 13, 2025 - Feb 17, 2025 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 301.21 |
ZacksALNY Reports Sustained 6-Month Efficacy Data From Amyloidosis Study
Alnylam shares interim phase I amyloidosis study data on nucresiran, showing rapid TTR reduction sustained for six months after a single dose.
Clinical Trials ArenaAlnylam reveals trial outcomes of nucresiran for ATTR amyloidosis treatment
The study showed significant reductions in serum TTR levels in subjects after a single dose, with sustained effects over time.
Advertisement
Advertisement
Advertisement
© 2024 Yahoo. All rights reserved.